Thank you for subscribing!
Finfeed Archived Mar 18, 2021
Australia’s federal government will grant $15M to clinical studies that explore the use of psychedelic drugs like magic mushrooms and ecstasy, to treat Australians with debilitating mental illnesses.
Finfeed Archived Mar 17, 2021
Creso Pharma's targeted acquisition, Halucenex Life Sciences has appointed True North Clinical Research to conduct PTSD trials
Next Investors Mar 15, 2021
Once again, medicinal cannabis company Creso Pharma (ASX: CPH) keeps pleasantly surprising us. Today they have REALLY surprised us by announcing they have acquired a Psychedelics company.
Finfeed Archived Mar 15, 2021
Creso Pharma Limited (ASX:CPH, FRA:1X8) has signed an agreement to acquire Halucenex Life Sciences Inc. (Halucenex), an established psychedelics company focused on developing treatments for Treatment Resistant Depression in individuals suffering from PTSD, and other mental health illnesses.
Get expert stock analysis direct in your inbox
Join Our Mailing List
